Dr Michael E. Belloy, PhD, from Stanford University, CA, speaks about differences in the genetic risk factors present in distinct populations and how, by acquiring data from patients of varied genetic backgrounds, we can determine which loci are most relevant for treating Alzheimer’s disease globally. By integrating genome-wide association (GWAS) data across varied populations and assessing linkage disequilibrium through meta-analysis, it becomes easier for scientists to identify and prioritize risk alleles without bias towards one ethnic group. Recorded at the Alzheimer’s Association International Conference (AAIC)® 2023 held in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.